Format

Send to

Choose Destination
Br J Cancer. 2017 Mar 28;116(7):964-971. doi: 10.1038/bjc.2017.35. Epub 2017 Feb 16.

Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.

Author information

1
Women's College Research Institute, Women's College Hospital, 76 Grenville, Toronto, ON, Canada.
2
Department of Nutritional Sciences, University of Toronto, Toronto, ON, Canada.
3
Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON, Canada.
4
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, 610 University Avenue, Toronto, ON, Canada.
5
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex, 600 University Avenue, Toronto, ON, Canada.
6
Dalla Lana School of Public Health, University of Toronto, 155 College Street, Health Science Building, Toronto, ON, Canada.
7
Public Health Ontario, Toronto, ON, Canada.
8
Department of Chronic Disease Epidemiology, Yale School of Public Health, 60 College Street, New Haven, CT, USA.

Abstract

BACKGROUND:

Various epidemiologic factors have been shown to influence the risk of ovarian cancer development. Given the high fatality associated with this disease, it is of interest to evaluate the association of prediagnostic hormonal, reproductive, and lifestyle exposures with ovarian cancer-specific survival.

METHODS:

We included 1421 patients with invasive epithelial ovarian cancer diagnosed in Ontario, Canada. Clinical information was obtained from medical records and prediagnostic exposure information was collected by telephone interview. Survival status was determined by linkage to the Ontario Cancer Registry. Proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for ovarian cancer-specific mortality associated with each exposure. Analyses were stratified by histologic subtype to further investigate the associations of risk factors on ovarian cancer-specific mortality.

RESULTS:

After a mean follow-up of 9.48 years (range 0.59-20.32 years), 655 (46%) women had died of ovarian cancer. Parity (ever) was associated with a significant 29% decreased mortality risk compared with nulliparity (HR=0.71; 95% CI 0.54-0.93; P=0.01). There was a borderline significant association between ever use of oestrogen-containing hormone replacement therapy (HRT) and mortality (HR=0.79; 95% CI 0.62-1.01; P=0.06). A history of cigarette smoking was associated with a significant 25% increased risk of death compared with never smoking (HR=1.25; 95% CI 1.01-1.54; P=0.04). Women with a greater cumulative number of ovulatory cycles had a significantly decreased risk of ovarian cancer-specific death (HR=0.63; 95% CI 0.43-0.94; P=0.02). Increasing BMI (kg m-2) 5 years before diagnosis was associated with an increased risk of death (HR=1.17; 95% CI 1.07-1.28; P=0.0007). Other hormonal or lifestyle factors were not significantly associated with ovarian cancer-specific mortality.

CONCLUSIONS:

Parity, ovulatory cycles, smoking, and BMI may affect survival following the diagnosis of ovarian cancer. Whether or not oestrogen-containing HRT use is beneficial for survival requires further evaluation.

PMID:
28208158
PMCID:
PMC5379147
DOI:
10.1038/bjc.2017.35
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center